http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
VistaGen Therapeutics to Present at the Jefferies London Healthcare Conference
-
VistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update
-
VistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update
-
VistaGen Therapeutics to Report Fiscal Year 2022 Second Quarter Financial Results and Recent Developments on November 10, 2021
-
VistaGen Therapeutics to Report Fiscal Year 2022 Second Quarter Financial Results and Recent Developments on November 10, 2021
-
VistaGen Therapeutics (VTGN) Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder
-
VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder
-
VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder
-
VistaGen Therapeutics (VTGN) Reports New Preclinical Mechanism of Action Data Supporting PH94B’s Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain
-
VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B’s Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain
-
VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B’s Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain
-
VistaGen Therapeutics (VTGN) Initiates PALISADE-2 Phase 3 Study for PH94B in Social Anxiety Disorder
-
VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2
-
VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2
-
VistaGen Therapeutics to Participate in Baird’s 2021 Global Healthcare Conference
-
VistaGen Therapeutics to Participate in Baird’s 2021 Global Healthcare Conference
-
VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update
-
VistaGen Therapeutics to Report Fiscal Year 2022 First Quarter Financial Results and Host Conference Call and Webcast on August 12, 2021
-
VistaGen Therapeutics to Report Fiscal Year 2022 First Quarter Financial Results and Host Conference Call and Webcast on August 12, 2021
-
VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference
-
VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference
-
VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors
-
VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors
-
VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021
-
VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021
-
VistaGen Therapeutics (VTGN) Announces Appointment of Mary L. Rotunno to its Board of Directors
-
VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors
-
VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors
-
VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update
-
VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update
-
VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021
-
VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021
-
VistaGen Therapeutics Set to Join the Russell 2000® Index
-
VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder
-
VistaGen Therapeutics to Present at Two Investor Conferences in June
-
VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer
-
VistaGen Therapeutics (VTGN) Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors
-
VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors
-
VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors
-
VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive Benzodiazepines
-
VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive Benzodiazepines
-
VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March
-
VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March
-
VistaGen Therapeutics (VTGN) Announces PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study
-
VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study
-
VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021
-
VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021
-
VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders
-
VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression
-
VistaGen Therapeutics Expands R&D Team with Appointment of Louis Monti, M.D., Ph.D., Pioneer in the Development of Neuroactive Steroids known as Pherines as Potential Treatments for Anxiety and De
